Putting Business Value at the Center of AI in Biopharma

Artificial intelligence may be moving quickly, but life sciences companies cannot afford to treat it as a race for the latest shiny tool. In this episode of Life Sciences DNA, Brinda Banerjee, CIO of Stemline Therapeutics, sits down with Srivatsan Nagaraja to discuss how an oncology-focused biopharma company can pursue AI with rigor, speed, and a clear connection to business and patient impact. Banerjee offers a practical framework for moving from enthusiasm to execution: start with the business problem, build trusted data and governance foundations, keep experts in the loop, and form agile, cross-functional teams that can test, learn, and scale what works.